GW Pharma (GWPH) PT Raised to $200 at Cowen

Cowen analyst Phil Nadeau raised the price target on GW Pharma (NASDAQ: GWPH) to $200.00 (from $175.00) while maintaining a Outperform rating following results.

The analyst commented, "GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). Epidiolex also met the primary endpoint in a Ph. III trial in TSC, and an sNDA filing is planned for Q4. Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued."

You May Also Be Interested In

• Affirm Holdings (AFRM) PT Raised to $124 at TD Cowen
• Assurant (AIZ) PT Raised to $320 at BMO Capital
• Elastic NV. (ESTC) PT Raised to $130 at Piper Sandler